Gene study in leprosy patients on treatment
Part of Infections clinical trials.
This study looks at certain genes (TGF beta 1) in people with leprosy who are already taking multidrug therapy. It aims to understand how these genes might affect the disease, which could lead to better treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with leprosy (Hansen's disease).
- You are 18 years or older.
- You are currently taking multidrug therapy (MDT) for leprosy.
- You do not have any other skin diseases.
- You do not have a leprosy reaction (sudden inflammation of skin or nerves).
- You are not pregnant or breastfeeding, and do not have an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a specific gene (Rab 32) affects how leprosy progresses. It may help doctors better predict outcomes for people with leprosy.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This trial tests a new vaccine (LEP-F1 + GLA-SE) to see if it is safe and helps the body fight leprosy. It is for healthy adults living in areas where leprosy is common.
This Phase 2 trial tests whether adding metformin to standard leprosy treatment (multidrug therapy, or MDT) helps people with multibacillary leprosy recover better and remain tolerable over 48 weeks. Participants also get monitored closely for side effects and safety issues.
This study tests a new way to diagnose leprosy by taking a tiny sample from a nerve under the skin using ultrasound guidance. The goal is to see if this method can accurately detect leprosy and help doctors know when treatment is working.
This Phase 3 study tests whether taking preventive antibiotics after possible contact can stop leprosy from developing. If it works, it could protect people in affected communities from getting leprosy (and possibly related infections).
Hear when a new Leprosy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.